FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 321:708-712 September 14, 1989 Number 11 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In previous studies of the antibody response to hepatitis B vaccine in 598 subjects who received a full course of vaccination, we observed a bimodal response, with about 14 percent producing less than approximately 1000 radioimmunoassay (RIA) units. An analysis of the major histocompatibility complex (MHC) HLA and complement types of 20 of the subjects with the lowest responses indicated a greater-than-expected number of homozygotes for the extended or fixed MHC haplotype [HLA-B8, SC01, DR3]. This finding suggested that the lack of a normal response was a recessive MHC-linked trait. In this study, we prospectively vaccinated five homozygotes and nine heterozygotes for this haplotype in the expectation that the homozygotes would produce much lower levels of antibody than the heterozygotes. When the antibody response was assessed two months after the third injection, four of the five homozygotes had produced very low levels (approximately 1000 units or less) of antibody (mean, 467 RIA units; range, less than 8 to 1266), whereas all nine heterozygotes produced more than 2500 RIA units (mean, 15,608; range, 2655 to 28,900) (P less than 0.01). We conclude that the usual response to hepatitis B surface antigen is due to the presence of a dominant immune-response gene in the MHC and that a low response is due to the absence of such a gene and the presence on both chromosomes of MHC haplotypes (such as [HLA-B8, SC01, DR3]) that indicate such a response.

Source Information

Center for Blood Research, Boston, MA 02115.

This article has been cited by other articles:

• Kim, H N., Harrington, R. D, Rompaey, S. E V., Kitahata, M. M (2008). Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 19: 600-604 [Abstract] [Full Text]  
• Vandiedonck, C., Beaurain, G., Giraud, M., Hue-Beauvais, C., Eymard, B., Tranchant, C., Gajdos, P., Dausset, J., Garchon, H.-J. (2004). Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia. Proc. Natl. Acad. Sci. USA 101: 15464-15469 [Abstract] [Full Text]  
• Karayiannis, P., Main, J., Thomas, H. C. (2004). Hepatitis vaccines. Br Med Bull 70: 29-49 [Full Text]  
• Thio, C. L., Thomas, D. L., Karacki, P., Gao, X., Marti, D., Kaslow, R. A., Goedert, J. J., Hilgartner, M., Strathdee, S. A., Duggal, P., O'Brien, S. J., Astemborski, J., Carrington, M. (2003). Comprehensive Analysis of Class I and Class II HLA Antigens and Chronic Hepatitis B Virus Infection. J. Virol. 77: 12083-12087 [Abstract] [Full Text]  
• Williams, O. M., Hart, K. W., Wang, E. C. Y., Gelder, C. M. (2002). Analysis of CD4+ T-Cell Responses to Human Papillomavirus (HPV) Type 11 L1 in Healthy Adults Reveals a High Degree of Responsiveness and Cross-Reactivity with Other HPV Types. J. Virol. 76: 7418-7429 [Abstract] [Full Text]  
• ROSENBERG, W (1999). Mechanisms of immune escape in viral hepatitis. Gut 44: 759-764 [Full Text]  
• Losonsky, G. A., Wasserman, S. S., Stephens, I., Mahoney, F., Armstrong, P., Gumpper, K., Dulkerian, S., West, D. J., Gewolb, I. H. (1999). Hepatitis B Vaccination of Premature Infants: A Reassessment of Current Recommendations for Delayed Immunization. Pediatrics 103: 14e-14 [Abstract] [Full Text]  
• Blondheim, O., Bader, D., Abend, M., Peniakov, M., Reich, D., Potesman, I, Handsher, R., Gidoni, I., Linder, N. (1998). Immunogenicity of hepatitis B vaccine in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 79: 206F-208 [Abstract] [Full Text]  
• Pirofski, L.-a., Casadevall, A. (1998). Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host. Clin. Microbiol. Rev. 11: 1-26 [Abstract] [Full Text]  
• Volti, S L., Caruso-Nicoletti, M, Biazzo, F, Sciacca, A, Mandarà, G, Mancuso, M, Mollica, F (1998). Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus. Arch. Dis. Child. 78: 54-57 [Abstract] [Full Text]  
• Johnson, C. E., Stancin, T., Fattlar, D., Rome, L. P., Kumar, M. L. (1997). A Long-term Prospective Study of Varicella Vaccine in Healthy Children. Pediatrics 100: 761-766 [Abstract] [Full Text]  
• Zuckerman, J. N, Sabin, C., Craig, F. M, Williams, A, Zuckerman, A. J (1997). Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. BMJ 314: 329-329 [Abstract] [Full Text]  
• Schur, P.H. (1995). Review: Genetics of systemic lupus erythematosus. Lupus 4: 425-437  
• Tan, K. L., Goh, K. T., Oon, C. J., Chan, S. H. (1994). Immunogenicity of Recombinant Yeast-Derived Hepatitis B Vaccine in Nonresponders to Perinatal Immunization. JAMA 271: 859-861 [Abstract]  
• Barie, P. S., Dellinger, E. P., Dougherty, S. H., Fink, M. P. (1994). Assessment of Hepatitis B Virus Immunization Status Among North American Surgeons. Arch Surg 129: 27-32 [Abstract]  
• Nagafuchi, S., Kashiwagi, S., Okada, K., Anzai, K., Nakamura, M., Nishimura, Y., Sasazuki, T., Niho, Y. (1991). Reversal of Nonresponders and Postexposure Prophylaxis by Intradermal Hepatitis B Vaccination in Japanese Medical Personnel. JAMA 265: 2679-2683 [Abstract]